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Abstract We evaluated correlations between positive find-
ings of changes on brain magnetic resonance imaging (MRI)
and selected morphological and electrophysiological parame-
ters of the retinal and visual systems in Wilson’s disease.
Fifty-eight Wilson’s disease symptomatic patients were
divided according to whether they displayed brain changes on
MRI (positive, n = 39; negative, n = 19). All participants and
healthy control group (n = 30), underwent retinal optical co-
herence tomography to assess the thickness of macula and the
total retinal nerve fiber layer. Visual evoked potentials were
measured and electroretinography was performed. Macular
and retinal nerve fibers were thinner in participants with
changes on MRI than in participants without changes.
Electrophysiological parameters were markedly different in
the MRI positive group compared with the negative
group and 30 healthy controls; however, some abnormalities
were evident in cases without visible brain pathology.
Morphological and electrophysiological changes of retinal
and visual pathways are associated with MRI visualized brain
injury in Wilson’s disease and may be useful for detecting the
degree of neurodegeneration.
Keywords Wilson’s disease . Brain magnetic resonance .
Optical coherence tomography .Pattern-reversal visual evoked
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Introduction
Copper is an essential trace element. However, due to its tox-
icity at higher concentrations, its level in the body must be
very strictly controlled (Valentine and Gralla 1997). Wilson’s
disease (WD) is an autosomal recessive genetic disorder
caused by mutations in the gene encoding the ATP7B protein,
which is responsible for copper transport and excretion (Bull
et al. 1993). As a result of defective protein production, excess
copper accumulates in the body, leading to damage to tissues
and organs; this damage occurs predominantly in the liver
(Ferenci 2005), and later becomes evident in the central ner-
vous system, cornea, and other organs (Scheinberg and
Sternlieb 1996; Litwin et al. 2013a). Therefore, the typical
clinical signs and symptoms of WD are hepatic, neuropsychi-
atric, and ophthalmological such as the Kayser-Fleischer ring
in the cornea (Scheinberg and Sternlieb 1984; Roberts and
Schilsky 2008; EASL Clinical Practice Guidelines 2012).
Currently, the most common investigations used to aidWD
diagnosis are measurements of serum ceruloplasmin and cop-
per concentrations, 24-h urinary copper excretion, as well as
DNA analysis, liver-function tests, detection of Kayser-
Fleischer rings, and magnetic resonance imaging (MRI) of
the brain (Ala et al. 2007). MRI also enables the detection of
brain pathology that develops in later stages of the disease
(Bandmann et al. 2015). Changes usually occur in the basal
ganglia (putamen, globus pallidus), thalamus, and pons and
appear in most WD patients with the neuropsychiatric form
(90–100 %) of the disease (Litwin et al. 2013b), but copper
accumulates in all parts of brain (Scheinberg and Sternlieb
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1984; Litwin et al. 2013a). Brain changes are less common in
the hepatic form (40–50 %) and rare in asymptomatic cases
(25 %) (Litwin et al. 2013a, b).
The embryological, structural, and functional continuity of
the retina with the central nervous system makes the visual
pathway a prime target for potential non-invasive investiga-
tions of neurodegeneration, such as the neurodegeneration
that occurs in the course of Alzheimer’s disease and multiple
sclerosis (Greenberg and Frohman 2010). Modern techniques
detect even very subtle changes in retinal and proximal visual
pathways. Morphological abnormalities of the retina can be
detected using optical coherence tomography (OCT), a
non-invasive imaging technique that utilizes illumination
with optical beams in a manner analogous to the me-
chanical waves of an ultrasound scanner (Gramatikov 2014).
The relatively low wavelength of visible light paired
with interference-based noise filtering yields crisp, high-
resolution images. Functional assessment of the retina can
be performed with established electrophysiological tech-
niques such as testing of visual evoked potentials (Halliday
1993) and electroretinography (ERG). Retinal copper deposi-
tion should affect the conduction properties of the retina,
which is an extension of the central nervous system
(Satishchandra and Ravishankar Naik 2000).
Although cortical accumulation of copper in the cornea is
typical forWD, retinal involvement inWD has not been wide-
ly investigated especially taking into account various stages of
the disease (Satishchandra, et al. 2000; Albrecht et al. 2012).
The aims of the present study were to assess the morpholog-
ical and functional status of retinal and visual pathway as
markers of neurodegeneration, to relate this status to the pres-
ence of lesions on brain MRI in a large cohort ofWD patients,
and to identify ophthalmological markers of WD.
Methods
This study was a cross-sectional, non-interventional, observa-
tional study approved by the Medical University of Warsaw
Bioethics Committee. All participants provided informed con-
sent. All consecutive symptomatic WD patients admitted to
the 2nd Department of Neurology, Institute of Psychiatry and
Neurology, Warsaw between 2012 and 2013 who were diag-
nosed according to established criteria (EASL Clinical
Practice Guidelines 2012) were enrolled in the study. The
disease was considered symptomatic if a patient had clinical
signs of WD at the time of diagnosis or earlier. We distin-
guished between neurological and hepatic predominant forms
of the disease according to the presence and intensity of indi-
vidual neuropsychiatric and hepatic signs at the time of diag-
nosis, as described elsewhere (Litwin et al. 2012).
The control group (CG) consisted of 30 age- and gender-
matched healthy volunteers.
All participants with WD underwent brain MRI with a
1.5 T Gyroscan ACS-NT (Philips Medical System, Best,
Netherlands). Images were obtained in T1, T2, FLAIR, and
T2* sequences, and were subsequently assessed with respect
to the presence of changes in 5-mm axial planes. Emphazise
was put on regions where most often pathological changes are
seen in WD as: lentiform and caudate nuclei, thalami,
substantia nigra, red nuclei, pons and cerebellum. Patients
were divided into two groups depending on the presence or
absence of MRI changes (MRI+ and MRI-, respectively).
Participants from both groups underwent routine ophthal-
mological examination to rule out ocular pathologies and pre-
vious ophthalmological surgery. Exclusion criteria were con-
traindications to the use of 1 % tropicamide, past ocular sur-
gery, ocular trauma, disease of the anterior and posterior eye
segments, and pregnancy. Patients with a refractive error
were accepted provided that the error did not exceed ±1.5
diopters. Only one patient (48 year old man) was excluded
from our study due to a refractive error of −1.75 D sph as well
as myopic retina degeneration, which may have affected
the results of our examinations, particularly the electro-
physiology. One eye was also excluded from the study due
to a history of cataract extraction followed by retinal
detachment.
OCT was performed using a Spectralis OCT (Cirrus HD-
OT Spectral Domain Technology, Zeiss, Germany) with soft-
ware version 5.11. Total thickness of the macula (Mth) and of
the retinal nerve fiber layer (RNFL) was measured separately.
Macular images were manually segmented to determine the
thickness of specific layers of the retina at the macula: the
ganglion cell and inner plexiform layer complex (GCIP), the
inner nuclear layer (INL), the outer plexiform layer (OPL),
and the outer nuclear layer plus the photoreceptor layer
(ONL + PRL). The thickness of all layers was measured at
the thickest point within the perifovea, with the exception of
the outer nuclear layer plus the photoreceptor layer, which was
measured at the center of the fovea. To maximize accuracy,
manual segmentation was performed on black-and-white im-
ages. RNFL measurement was performed after manually cen-
tering the optic disc. Thickness values for four quadrants (su-
perior, temporal, inferior, and nasal) were automatically gen-
erated by the software.
Electrophysiological studies included pattern-reversal visu-
al evoked potentials (PVEP) and flash full-field ERG.
Electrophysiological investigations were performed according
to standards set by the International Society for Clinical
Electrophysiology of Vision using the RetiScan RetiPort gam-
ma plus2 system (Roland Consult, Germany) to obtain elec-
trophysiological data during both PVEP assessment and ERG
(Odom et al. 2010; McCulloch et al. 2015).
PVEP peak latencies of N75, P100, and N135 waves were
measured, as were N75-P100 wave amplitudes. One hundred
responses were obtained and averaged for each eye. ERG was
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performed under both scotopic (dark-adapted) and photopic
(light-adapted) conditions. The light stimulus was generated
with a whole-field Ganzfeld stimulator. Measurements of re-
sponses to both low-intensity (0.01 cd·s·m−2; dark-adapted
0.01 ERG) and high-intensity (3.0 cd·s·m−2; dark-adapted
3.0 ERG) stimuli were obtained under scotopic conditions;
the 3.0 cd·s·m−2 stimulus was also evaluated under photopic
conditions (light-adapted 3.0 ERG). B-waves were evaluated
in response to the low-intensity stimulus under scotopic
conditions, while both a- and b-waves were analyzed
with the high-intensity stimulus under scotopic and
photopic conditions. Amplitude and latency were measured
for each wave trace and for the first three oscillatory potentials
(O1, O2, and O3).
Statistical analysis
All individual measurements of thickness (OCT), and electro-
physiological parameters (PVEP, ERG) are average values
from the left and right eyes. The normality of the distribution
of each variable in each group was assessed using the Shapiro-
Wilk test. Comparisons of the OCT, PVEP, and ERG results
between the MRI+ and MRI- groups and between the
MRI- and CG groups were performed using Student’s t
test (if variables fulfilled the assumptions of normal
distribution) or Mann-Whitney test (if variables did not fulfill
the assumptions of normal distribution). Univariate cor-
relations between each of the OCT variables and each
of the PVEP, and ERG parameters were evaluated using
Spearmann’s correlation coefficients. Average values of
the data measured in both eyes (except for one data
point due to the exclusion of a single eye as described
earlier), were analyzed. Additionally to investigate po-
tential correlation between age and RNFL or Mth
Spearman’s rho coefficient was calculated in the control
group. The data are presented as means and standard
deviation (SD). P-values below 0.05 were considered
statistically significant.
Results
The studied cohort consisted of 58 patients (including 34 fe-
males; mean age 38.7 years) and was divided into MRI+
(n = 39; including 22 females) and MRI- (n = 19; including
12 females). The control group (CG) consisted of 30 partici-
pants (including 18 females), with a mean age of 39.6 years.
Patient characteristics as well as kind of WD treatment are
presented in Table 1.
Total RNFL (p = 0.001) was thinner in the MRI+ group
compared to the MRI-group. The RNFL measured in the su-
perior (p = 0.024) and temporal (p = 0.006) quadrants was also
thinner in the MRI+ group. Mth in the MRI+ group was thin-
ner compared to the MRI- group (p < 0.001). The manually
segmented individual layers were also thinner in the MRI+
group (p < 0.05, except for OPL, where p = 0.085). No dif-
ferences were found in the thickness of RNFL and Mth be-
tween the MRI- and CG. A detailed breakdown of the OCT
results is presented in Table 2, examples of OCT (physiolog-
ical - for MRI negative patient and pathological for MRI pos-
itive patient) are shown in Figs. 1 and 2.
Latencies of all the measured PVEP components were
prolonged in the MRI+ group. N75 latency (p < 0.001),
P100 latency (p < 0.001), and N135 latency (p = 0.019) were
all prolonged when compared to the MRI- group. Contrary to
the effect seen for latencies, the N75-P100 amplitude was not
different between both groups. Only N135 latency was
prolonged in the MRI- group when compared to the CG
(p < 0.001), no other differences were observed between the
MRI- group and CG. Detailed PVEP results are presented in
Table 3.
In general, ERG latencies were prolonged in the MRI+
group while amplitudes were diminished, when compared to
the MRI- group.
Dark-adapted 0.01 ERG demonstrated increased b-wave
latency (p < 0.001) and reduced b-wave amplitude
(p = 0.033) in the MRI+ group compared to the MRI- group
(Table 4).
Table 1 Patient characteristics
[data shown as mean (SD)] MRI+ (n = 39) MRI- (n = 19)
Age (years) 42.1 (10.71) 31.1 (8.84)
Age at disease onset (years) 31.2 (9.09) 20.3 (8.55)
Age at disease diagnosis (years) 33.3 (10.02) 20.4 (7.03)
Neuropsychiatric form (n) at diagnosis 32 0
Hepatic form (n) at diagnosis 7 19
Neurologic signs and symptoms at ophthalmological assessment (n) 35 1
Duration of disease (years) 10.7 (9.95) 11.1 (10.34)
WD treatment (DPA/ZS) 26/13 6/13
SD standard deviation, n number of patients, MRI magnetic resonance image, MRI+ patients with pathological
findings on MRI, MRI- patients without pathological findings on MRI, DPA-d penicillamine, ZS zinc sulphate
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Dark-adapted 3.0 ERG showed a prolonged latency of both
the a-wave (p < 0.001) and b-wave (p < 0.001) in the MRI+
group compared to the MRI-group. No differences however,
were observed for the amplitude values between these groups.
When compared to the CG though, the MRI- group showed
prolonged a-wave latency (p = 0.017), and reduced a-wave
amplitude (p < 0.001). No differences in the b-waves param-
eters were seen (Table 4). In the dark-adapted 3.0 ERG
prolonged latencies of the O1 (p = 0.001), O2 (p = 0.001),
and O3 (p = 0.030) oscillatory potentials were also observed
in the MRI+ group, in addition to reduced amplitudes of the
O1 (p = 0.008) and O2 (p = 0.049) potentials. The O2
(p = 0.001) and O3 (p < 0.001) amplitudes were also reduced
in the MRI- group when compared to the CG (Table 4). In the
light-adapted 3.0 ERG test, the latencies of the a-wave
(p = 0.001) and b-wave (p = 0.008) were also prolonged in
the MRI+ group with respect to the MRI- group. The respec-
tive amplitudes were diminished (a-wave: p = 0.002; b-wave:
p = 0.015). The a-wave latency was prolonged (p = 0.015),
and the b-wave amplitude diminished (p = 0.020) in the MRI-
group in comparison to the CG. Detailed ERG results are
presented in Table 4, while examples of ERG (physiological
for MRI negative patient and pathological for MRI positive
patient) are shown in Fig. 3. Additionally, in the entire cohort,
the P100 latency measured on PVEP correlated negatively
with the OCT measurements of RNFL (R = −0.70,
p < 0.001; Fig. 4a) and Mth (R = −0.46, p < 0.001; Fig. 4b).
Finally, there was no correlation between age and RNFL
(R = −0,28, p = 0139) or Mth (R = −0,25, p = 0186) in CG.
Discussion
Our findings confirm morphological and functional status of
retinal and visual pathways in patients with WD, which are
more pronounced in individuals with brain MRI pathology.
While Albrecht et al. demonstrated OCT and electrophysiolo-
gy changes in WD patients, their findings did not consider
clinical variations between their patients, treating them as a
uniform group. Furthermore, their electrophysiology exami-
nations only tested VEP, and did not include ERG testing in
order to investigate the retina. Our cohort of 58 patients was
larger, homogenous (no asymptomatic individuals) and the
performed electrophysiological examinations encompassed
both VEP and ERG, which allowed us to evaluate WD pa-
tients’ retinas from a physiological point of view. We focused
mainly on morphological and physiological changes present
in patients with pathological lesions evident on brain MRI
compared with WD patients without visible lesions and with
age- and gender-matched healthy controls. Although the mean
age variance between the MRI+ and MRI- groups was
11 years, numerous authors as well as our analysis state that
age is not an influential factor for OCT, RNFL thickness and
electrophysiology (Sabates et al. 2011; Feuer et al. 2011;
Freud et al. 2011; Kanamori et al. 2003), Mailankody et al.
2015.
In terms of morphology, considerable thinning of the mac-
ula and RNFL occurred in the MRI+ group (Table 2). The
RNFL ismainly composed of unmyelinated axons of ganglion
cells located in the ganglion cell layer. Measuring RFNL
Table 2 Results of Ocular Coherent Tomography (OCT) in WD patients with and without MRI pathology
WD Group CG and MRI-
MRI+ (N = 39) MRI− (N = 19) MRI+ vs. MRI- CG MRI- vs. CG
Parameter Mean SD Mean SD Difference P Mean SD Difference p
Retinal nerve fiber layer measurements
RNFL (μm) 89.13 8.80 96.34 6.41 −7.21 0.001 96.07 5.05 0.27 0.967
S 109.97 11.04 118.05 12.58 −8.08 0.024 114.18 11.06 3.87 0.263
T 62.85 9.00 71.66 11.23 −8.81 0.006 73.85 4.53 −2.19 0.426
I 116.61 13.54 122.32 9.45 −5.71 0.074 120.55 8.27 1.77 0.460
N 71.74 10.28 73.68 8.85 −1.94 0.467 76.27 4.86 −2.59 0.255
Macular thickness measurements
Mth (μm) 254.82 16.26 273.50 18.57 −18.68 0.001 279.50 11.04 −6.00 0.103
GCIP 78.61 3.34 83.45 2.14 −4.84 <0.001 82.95 2.75 0.50 0.483
INL 33.00 2.33 36.92 1.59 −3.92 <0.001 37.28 1.07 −0.36 0.364
OPL 30.56 1.45 31.16 1.05 −0.60 0.085 30.75 1.28 0.41 0.399
ONL + PRL 118.50 3.92 121.21 4.42 −2.71 0.031 119.15 2.99 2.06 0.122
MRI magnetic resonance image, MRI+ patients with pathological findings on MRI, MRI- patients without pathological findings on MRI, CG control
group, RNFL retinal nerve fibre layer, S superior part, T temporal part, I inferior part, N nasal part,Mth total macular thickness, GCIP ganglion cell and
inner plexiform layer, INL inner nuclear layer, OPL outer plexiform layer, ONL + PRL outer nuclear layer and photoreceptor layer, SD standard
deviation, Statistically significant differences are represented in bold
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thickness by the OCT method gives us an objective
estimation of the integrity of unmyelinated axons.
Retinal architecture, which can also be assessed by
OCT, estimates neuronal integrity of the retina. The
largest contributor to reduced Mth in both absolute
and relative terms came from the GCIP and the inner
nuclear layer. The inner nuclear layer consists of tightly
packed cell bodies of bipolar, horizontal, and amacrine
cells (Kaufman and Alm 2003). Interestingly, the only
assessed layer that did not significantly differ between
the groups was the OPL. This is in line with the work
of (Albrecht et al. 2012). The OPL is the junction between the
photoreceptor and the bipolar and horizontal cells. The outer
two-thirds of the OPL consist of photoreceptor axons and
Muller cell processes (Henle fiber layer), while the rest of
the OPL (dendritic OPL) consists of dendrites from the hori-
zontal and bipolar cells of the of INL, as well as Muller cell
processes (Kaufman and Alm 2003). As the OPLmorphology
was unchanged in both groups of patients, it may be less
affected by copper toxicity than other layers.
There were no abnormal morphological findings in MRI-
patients compared to the CG, which may suggest that retinal
thinning occurs in more advanced stages of WD or predomi-
nantly in patients with more severe brain pathology that is
visible on MRI.
There are various clinical forms of WD, and suffering from
WD does not automatically affect macular and RNFL thick-
ness. In our study, the MRI- group of WD patients did not
appear to differ from the CG with respect to RNFL thickness,
suggesting that our finding of RNFL thinning is specifically
related to brain changes evident on MRI. Our observation of
thinner RNFLs in MRI+ patients supports previous observa-
tions that chronic copper-related degeneration affects unmy-
elinated fibers (Valenti 2011; Garcia-Martin et al. 2014).
Fig. 1 a Physiological central
macular thickness 268 μm for
MRI negativeWD patient (arrows
show central subfield thickness);
b Pathological central macular
thickness 201 μm for MRI
positiveWDpatient (arrows show
central subfield thickness)
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Fig. 2 a Physiological RNFL for
MRI negativeWD patient (arrows
illustrate 107 μm for right eye and
108 for left eye; b Pathological
RNFL for MRI positive WD
patient (arrows illustrate 78 μm
for right eye and 78 for left eye)
Table 3 Visual evoked potential latencies (ms) and amplitudes (μV) in Wilson Disease with and without pathological changes in brain MRI
WD Group CG and MRI-
MRI+ (N = 39) MRI− (N = 19) MRI+ vs. MRI- CG MRI- vs. CG
Parameter Mean SD Mean SD Difference p Mean SD Difference p
N75 (ms) 78.40 3.25 75.05 2.62 3.35 <0.001 74.73 1.73 0.32 0.643
P100 (ms) 114.07 7.06 106.44 4.09 7.63 <0.001 105.79 2.26 0.65 0.902
N135 (ms) 148.40 3.78 145.58 3.82 2.82 0.019 138.97 3.73 6.61 <0.001
Amplitude N75 - P100 (μV) 9.67 2.09 10.20 2.33 0.53 0.411 9.30 1.62 0.90 0.152
MRI magnetic resonance image, MRI+ patients with pathological findings on MRI, MRI- patients without pathological findings on MRI, CG control
group, N75 N75 wave latency, P100 P100 wave latency, N135 N135 wave latency, N75-P100 amplitude amplitude between peaks of N75 and P100
waves, SD standard deviation, ms milliseconds, μV microvolts. Statistically significant differences are represented in bold
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However, while hepatic forms of WD should theoretically
lead to smaller OCT changes, more advances stages of the
disease (without neurological signs but with MRI pathology),
even in this form, may bring OCT abnormalities.
Interestingly, retrograde thinning of the RNFL was previ-
ously proposed to be an early marker of neurodegeneration
(Valenti 2011). It is considered to be one of the earliest signs of
Alzheimer’s disease, occurring even prior to hippocampal
damage that impacts memory (Valenti 2011). We speculate
that this finding may reflect differential susceptibility of the
RNFL to different mechanisms of neurodegeneration. Patients
with multiple sclerosis also exhibit thinning of the retina ver-
sus healthy controls. However, this effect is most pronounced
in patients with a history of optic neuritis in the course of their
disease (Garcia-Martin et al. 2014).
Functional impairment of retinal and visual pathways, was
demonstrated by differences in PEVP and ERG between
MRI+ and MRI- subjects in the present investigation, con-
firms the multifocal character of WD.
Various ERG waves are known to originate in morpholog-
ically distinct regions of the retina. Alterations in the a-wave
reflect changes in the receptor cell layer, those in the b-wave
correspond to bipolar and horizontal cell pathology, and oscil-
latory potentials are thought to originate from amacrine cells.
Many neurodegenerative diseases (e.g. multiple sclerosis)
may initially show functional changes detected only by elec-
trophysiological methods, without evident morphological or
clinical abnormalities (Simo et al. 2008). Upon comparing the
results of the MRI- patients to the control group, only electro-
physiological changes (a- wave in sc max, pht a- and b- waves
and OP) were discovered, while the OCT was unchanged
(Tables 3 and 4). This may point to functional abnormalities,
particularly in the receptor and amacrine cells, which
could confirm that electrophysiological changes may oc-
cur earlier than morphological disorders. Differences be-
tween the CG and the MRI- group, as well as between the
MRI- and MRI+ groups, could be regarded as the earliest
electrophysiological manifestations of WD. These changes
include the amplitudes of oscillatory potentials and a-wave
amplitude under 3.0 dark-adapted conditions. ERG sc max
a-wave amplitude and latency, as well as OP changes, point
towards initial visual system damage in the MRI- group.
Table 4 Electroretinography latencies and amplitudes in Wilson disease with and without pathological changes in brain MRI
WD Group CG and MRI-
MRI+ (N = 39) MRI− (N = 19) MRI+ vs. MRI- CG MRI- vs. CG
Parameter Mean SD Mean SD Difference p Mean SD Difference p
Dark-adapted 0.01
sc b lat. (ms) 87.96 5.50 81.41 3.29 6.55 <0.001 78.42 5.49 2.99 0.023
sc b amp. (μV) 204.53 56.62 242.00 59.21 −37.47 0.033 242.83 56.73 −0.83 0.926
Dark-adapted 3.0
sc max a lat. (ms) 21.82 1.62 19.77 1.70 2.05 <0.001 20.99 1.24 −1.22 0.004
sc max a amp. (μV) 238.38 74.64 271.32 81.98 −32.94 0.117 343.37 35.50 −72.05 0.001
sc max b lat. (ms) 45.09 2.99 41.72 2.67 3.37 <0.001 40.54 3.43 1.18 0.377
sc max b amp. (μV) 444.85 118.10 492.50 133.60 −43.65 0.232 562.60 76.99 −70.1 0.058
O1 lat. (ms) 20.03 2.23 18.39 0.87 1.64 0.001 18.21 0.46 0.18 0.418
O1 amp. (μV) 22.19 7.65 28.69 8.43 − 6.5 0.008 30.66 5.31 −1.97 0.371
O2 lat. (ms) 25.76 1.43 24.56 0.90 1.2 0.001 24.73 0.93 −0.17 0.542
O2 amp. (μV) 52.27 23.40 68.13 29.84 - 15.86 0.049 95.50 24.16 −27.37 0.006
O3 lat. (ms) 32.50 1.33 31.73 1.03 0.77 0.030 31.49 0.90 0.24 0.417
O3 amp. (μV) 23.02 11.65 27.88 14.30 −4.86 0.377 49.92 17.68 −22.04 <0.001
Light-adapted 3.0
pht a lat. (ms) 16.23 1.12 15.46 0.70 0.77 0.001 15.03 0.60 0.43 0.018
pht a amp. (μV) 43.48 14.34 56.75 14.07 −13.27 0.002 56.08 8.46 0.67 0.853
pht b lat. (ms) 31.34 0.96 30.46 1.16 0.85 0.008 30.45 1.06 0.01 0.983
pht b amp. (μV) 167.66 40.45 203.95 53.80 −36.29 0.015 234.47 41.01 −30.52 0.043
MRI magnetic resonance image; MRI+ patients with pathological findings on MRI, MRI- patients without pathological findings on MRI, CG control
group, sc b lat. b wave latency, sc b amp b-wave amplitude. Lat. latency, amp. amplitude, O1, O2, O3 first, second and third oscillatory potential
respectively, SD standard deviation, ms milliseconds, μV microvolts. Statistically significant differences are represented in bold
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Oscillatory potentials that are most likely generated by
amacrine cells, appear to reflect the activity of the negative
feedback exerted by amacrine cells towards bipolar and gan-
glion cells. Importantly, impairment of oscillatory potentials is
a very sensitive marker that reflects very early pathology re-
lated to oxidative stress; for example, reductions in oscillatory
potentials occur in the initial stages of diabetic retinopathy
(Langwinska-Wosko 1993). The observed changes are sensi-
tive markers of initial disorders of the retina therefore may be
present at early stages of WD when brain pathology is not
evident.
Other differences between the MRI- group and the CG
observed here can be regarded as intermediate changes in
which differences occur across the spectrum ofWD (photopic
a-wave latency and b-wave amplitude). The remaining param-
eters only differed between the MRI+ and MRI- groups, indi-
cating that they are specific correlates of changes on MRI that
are typical for advanced WD.
From our data, we cautiously conclude that amacrine cells
are among the first cells to be affected by WD. Furthermore,
cones may be more vulnerable than rods (earlier findings in
photopic 3.0 ERG) as our electrophysiology examinations,
Fig. 3 a Physiological ERG for MRI negativeWD patient; b Pathological ERG for MRI positive patient (decreased amplitudes of a-wave and b-wave)
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showed most changes to pht a latency and pht b amplitude –
characteristic of cone function. Meanwhile, rod functions are
portrayed by sc b, which were normal in MRI- patients.
Whether ERG alterations reflect a conduction defect within
cells, or a defect in synaptic transmission, remains to be elu-
cidated. It seems likely that the observed pathology is predom-
inantly intracellular in origin, as copper accumulates within
the cell in WD (Zischka and Lichtmannegger 2014; Dusek
et al. 2015).
General electrophysiological status of the visual pathway
also seems to reflect changes to the central nervous system
visible on MRI, corroborating the notion of continuity be-
tween the brain and the retina. Increased latency without con-
comitant decreased amplitude of PVEP waves clearly points
to a conduction defect in visual pathways. Two mechanisms
have been postulated to account for this effect. The first hy-
pothesis predicts that copper deposits directly affect conduc-
tion, while the second identifies secondary demyelination as
the culprit (Albrecht et al. 2012). The latter explanation seems
particularly attractive because similar electrophysiological
changes were observed in multiple sclerosis (Garcia-Martin
et al. 2014). It also provides an elegant explanation of
why latencies are affected but not amplitudes: demyelin-
ation is fundamentally a problem of conduction velocity.
Interestingly, while changes visible on MRI correlated with
all PVEP wave latencies in the present investigation, we also
detected a significant difference in N135 latency between the
MRI- group and the CG, suggesting that increased latency of
the N135 wave may be an early electrophysiological manifes-
tation of WD progression. This increased latency increased as
MRI changes became more visible, making it a potentially
useful marker of WD severity. Unfortunately, the N135 wave
is regarded to be the least stable of PVEP waves.
Prolonged latency of the P100 wave is considered to be the
most robust and clinically relevant marker of severe impair-
ment of visual-pathway function. This conclusion is consis-
tent with our observation that P100 waves were only delayed
in the MRI+ group (reflecting advanced pathology), as well as
with the strong correlations with retinal thinning detected
here. RNFL and macula thinning would therefore result in
conduction delays within visual pathways.
Existing research suggests that neurodegeneration in WD
may be reflected in measurable retinal and PVEP findings
(Topcu et al. 2002; Albrecht et al. 2012). Significant retinal
thinning was previously observed in WD patients via OCT
(Albrecht et al. 2012). Furthermore, children withWD exhibit
prolonged latencies of all visual evoked potential waves com-
pared to healthy controls (Albrecht et al. 2012). Similarly,
significant changes are evident on ERG, particularly under
dark-adapted conditions, and are reversible with treatment
(Satishchandra and Ravishankar Naik 2000), highlighting
the usefulness of retinal investigations during treatment mon-
itoring. Pre-symptomatic siblings of WD patients are also
more likely to exhibit changes in visual evoked potential
curves (Topcu et al. 2002), suggesting that these data would
be useful when screening at-risk populations.
Our work provides evidence that WD patients with patholog-
ical changes on brain MRI tend to perform worse on various
ophthalmological tests than WD patients with normal MRI. We
also identified electrophysiological pathology in patients with no
lesions visible on MRI. In general, at least some electrophysio-
logical findings preceded the onset of changes evident on OCT
and MRI, and morphological retinal changes were generally ab-
sent unless changes on MRI had already emerged. Correlations
between OCT and electrophysiological changes across our pop-
ulation point toward a singular underlying pathology.
Fig. 4 aCorrelation between P100 latency and RNFL thickness in patients withWD. bCorrelation between P100 latency and total macular thickness in
patients with Wilson’s disease
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Regarding the limitations of our study, we note that
while we conducted detailed ophthalmological investiga-
tions, we only concentrated on the correlation of these
data with MRI-detectable brain pathology not with clin-
ical presentation. We also did not perform analysis of
retinal changes with clinical form of WD (hepatic vs.
neuropsychiatric), however most our MRI positive
patients had neurological signs on diagnosis (36/58;
62 %). Such study should be done before starting treat-
ment. Our patients were treated for several years, and
their initial symptoms changed, so we concentrated only
on brain pathology. Only prospective long term study
on patients who just starts anti-copper therapy, may pro-
vide some information about role of copper intoxication
on retinal pathology and function in WD and to test if
ophthalmological tests could be used as potential marker
of treatment effectiveness.
Summarized, our study confirmed that OCT, ERG, and
PVEP are potentially valuable clinical tools for the investiga-
tion of organ injury in WD and provides a foundation for
investigating further correlations between retinal pathology
and clinical characteristics of WD patients, as well as patient
response to anti-copper therapy.
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